<DOC>
	<DOC>NCT01424397</DOC>
	<brief_summary>This study is designed to look at the affect of SB-705498 on allergic rhinitis symptoms induced by an allergen chamber challenge.</brief_summary>
	<brief_title>Intranasal SB-705498 in Allergic Rhinitis (AR) Patients</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis, Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<criteria>1. Diagnosis of AR, as determined by the presence of rhinitis symptoms that last for several months per year, for more than 1 year and are not attributed to allergy, infections or nasal abnormalities. 2. TNSS score of &gt;=4 following screening allergen challenge chamber. 3. Positive skin prick test for seasonal pollen 4. Positive RAST for seasonal pollen 5. Healthy as determined by responsible physician with the exception of mild asthma and AR 6. Male or female between 18 and 65 years of age inclusive. 7. A female subject is eligible to participate if she is of: Nonchildbearing potential defined as premenopausal females with a \documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea [in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) &gt; 40 MlU/ml and estradiol &lt; 40 pg/ml (&lt;147 pmol/L) is confirmatory]. Childbearing potential and agrees to use one of the contraception methods listed as instructed. Female subjects must agree to use contraception until 84 days postlast treatment administration. 8. Male subjects with female partners of childbearing potential must agree to use one contraception as instructed. This must be followed from the time of the first dose of study medication until 84 days postlast treatment administration. 9. Body weight ≥ 50 kg (males) and ≥45kg (females) and BMI within the range 19 29.9 kg/m2 (inclusive). 10. Screening prechallenge FEV1 greater than or equal to 80% and baselines FEV1/FVC greater than or equal to 70% of predicted value. 11. Capable of giving written informed consent. 12. Average QTcB, &lt; 450 msec; or QTc &lt; 480 msec in subjects with Bundle Branch Block. 13. AST and ALT &lt; 2xULN; alkaline phosphatase and bilirubin less than or equal to 1.5xULN 1. Nasal abnormalities likely to affect the outcome of the study, 2. History of frequent nosebleeds. 3. Respiratory disease other than mild asthma 4. A positive prestudy Hepatitis B or Hepatitis C result within 3 months of screening 5. Current or chronic history of liver disease, or known hepatic or biliary abnormalities 6. Positive prestudy drug/alcohol/smoking screen. 7. A positive test for HIV antibody. 8. History of regular alcohol consumption within 6 months of the study defined as: • An average weekly intake of &gt;14 drinks for males or &gt;7 drinks for females. 9. The subject has participated in a clinical trial and has received an investigational product within 30 days, 5 halflives or twice the duration of the biological effect of the investigational product prior to D1. 10. Exposure to more than four new chemical entities within 12 months prior to D1. 11. Use of prescription or nonprescription drugs, including vitamins, herbal and dietary supplements within 7 days prior to the first dose of study medication. 12. History of sensitivity to any of the study medications, or components 13. Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period. 14. Pregnant females as determined by positive serum or urine hCG test at screening or prior to dosing. 15. Lactating females. 16. Subject is mentally or legally incapacitated. 17. Urine cotinine levels indicative of smoking</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>